Mylan receives FDA approval for generic version of Imitrex
PITTSBURGH A major generic drug maker announced that it has received FDA approval for its version of a popular migraine drug.
Mylan has received approval from the Food and Drug Administration for sumatriptan succinate tablets in 25-, 50- and 100-mg strengths. The drug is a generic version of GlaxoSmithKline’s Imitrex.
Currently, Mylan has 120 ANDAs pending FDA approval representing $85.6 billion in annual brand sales, according to IMS Health. Thirty-four of these pending ANDAs are potential first-to-file opportunities, representing $17.3 billion in annual brand sales, according to IMS Health.
Asteres to debut new automated pharmacy kiosk at NACDS Pharmacy & Technology Conference
SAN DIEGO A company that makes automated pharmacy kiosks plans to unveil its latest products at an upcoming conference.
Asteres, which makes the ScriptCenter kiosk, announced this week that it would debut ScriptCenter 24/7 Automated Pharmacy Services at the 2009 National Association of Chain Drug Stores Pharmacy & Technology Conference in Boston, which begins Saturday.
“To date, ScriptCenter has enabled retailers to reduce pharmacy hours and increase customer services,” Asteres CEO Mark de Bruin said in a statement. “The addition of 24/7 Automated Pharmacy Services will expand customer engagement opportunities and drive incremental store sales leveraging kiosk, online and cell technologies.”
The services include the Express Prescription Pickup, Prescription Drop Off Anytime, one-touch pickup for families, ScriptCenter.com and others.
Sciele Pharma announces availability of head lice treatment
NEW YORK A new drug for treating head lice has become available from a subsidiary of a Japanese drug company.
Sciele Pharma, part of Shionogi, announced this week the availability of Ulesfia (benzyl alcohol lotion 5%). The medication kills head lice by asphyxiation without potential neurotoxic side effects, the company said.
Head lice infestation affects 6 to 12 million children between the ages of 3 and 12 every year. To breathe, head lice use breathing holes that close upon contact with most liquids, which allows them to go into suspended animation and survive for hours without respiration, but Ulesfia prevents them from closing their breathing holes, causing the insects to asphyxiate.